A citation-based method for searching scientific literature

David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
Times Cited: 292

Karen M Hallow, Gabriel Helmlinger, Peter J Greasley, John J V McMurray, David W Boulton. Diabetes Obes Metab 2018
Times Cited: 153

List of shared articles

Times cited

Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors.
Davide Margonato, Giuseppe Galati, Simone Mazzetti, Rosa Cannistraci, Gianluca Perseghin, Alberto Margonato, Andrea Mortara. Heart Fail Rev 2021

Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics.
Manfred Hecking, Adnan Sharif, Kathrin Eller, Trond Jenssen. Transpl Int 2021

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021

Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
Rumyana Dimova, Tsvetalina Tankova. Horm Metab Res 2021

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial.
Rosalie A Scholtes, Marcel H A Muskiet, Michiel J B van Baar, Anne C Hesp, Peter J Greasley, Cecilia Karlsson, Ann Hammarstedt, Niki Arya, Daniël H van Raalte, Hiddo J L Heerspink. Diabetes Care 2021

Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure.
Shruti S Joshi, Trisha Singh, David E Newby, Jagdeep Singh. Heart 2021

Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept.
Georgia Anastasiou, Erifili Hatziagelaki, Evangelos Liberopoulos. J Cardiovasc Pharmacol 2021

The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure.
Petter Bjornstad, Peter J Greasley, David C Wheeler, Glenn M Chertow, Anna Maria Langkilde, Hiddo J L Heerspink, DaniëL H Van Raalte. J Card Fail 2021

2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.
Chern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, Tsung-Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih-Hsien Sung, Hung-I Yeh, Yi-Heng Li, Ping-Yen Liu,[...]. J Chin Med Assoc 2020

Sodium-glucose co-transporter-2 inhibitors: peculiar "hybrid" diuretics that protect from target organ damage and cardiovascular events.
Riccardo Sarzani, Federico Giulietti, Chiara Di Pentima, Francesco Spannella. Nutr Metab Cardiovasc Dis 2020

What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
Muhammad Shahzeb Khan, Muthiah Vaduganathan. Curr Diab Rep 2020

SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.
Theodosios D Filippatos, Angelos Liontos, Ioanna Papakitsou, Moses S Elisaf. Postgrad Med 2019